Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. 2001. Acute disseminated encephalomyelitis: A follow-up study of 40 adult patients. Neurology 56(10):1313–8.

Shaw FE Jr, Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz GC, Hadler SC, Kuritsky JN, Hiner EE, Bregman DJ, Maynard JE. 1988. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 127(2):337–52.

Sheedy K on behalf of CDC. Personal communication regarding vaccine exemptions. 2002.

Silverman NS, Darby MJ, Ronkin SL, Wapner RJ. 1991. Hepatitis B prevalence in an unregistered prenatal population. Implications for neonatal therapy. JAMA 266(20):2852–5.

Singh B. 2000. Stimulation of the developing immune system can prevent autoimmunity. J Autoimmun 14(1):15–22.

Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 17:2908–2917.

Soubeyrand B, Boisnard F, Bruel M, Debois H, Delattre D, Gauthier A, Soum S, Thebault C. 2000. Translated from [Central nervous system demyelinating disease following hepatitis B vaccination with GenHevac B. Review often years of spontaneous notifications (1989–1998)]. Presse Med 29(14):775–80.

Spence MR, Dash GP. 1990. Hepatitis B: Perceptions, knowledge and vaccine acceptance among registered nurses in high-risk occupations in a university hospital . Infect Control Hosp Epidemiol 11(3):129–33.

Sturkenboom MCJM, Abenhaim L, Wolfson C, Roulet E, Heinzelf O, Gout O. 1999. Vaccinations, demyelination, and multiple sclerosis study (VDAMS). Pharmacoepidemiol Drug Safety; 8:S170–S171.

Stuve O, Zamvil SS. 1999. Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol 12(4):395–401.

Sutter RW, Cochi SL, Melnick JL. 1999. Live attenuated poliovirus vaccines. In Plotkin S, Orenstein W. Vaccines. 3rd ed. New York: W.B. Saunders Company. Pp. 364–408.

Tartaglino LM, Heiman-Patterson T, Friedman DP, Flanders AE. 1995. MR imaging in a case of postvaccination myelitis. Am J Neuroradiol 16(3):581–2.

Taylor H, Leitman R. 2002. Cyberchondriacs continue to grow in America. Health Care News 2(9):1–4.

Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L, Borras C, Grive E, Capellades J, Montalban X. 2000. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. R Am J Neuroradiol 21(4):702–6.

Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba-Zizen MT, Cabanis EA. 1999. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? Neurology 53(2):396–401.

Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alperovitch A. 2000. Translated from [The first episode of central nervous system demyelinization and hepatitis B virus vaccination]. Rev Neurol (Paris) 156(3):242–6.


U.S. Preventive Sevices Task Force. 1996. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams and Wilkins.


Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2(3):261–70.

Vella AT, Mitchell T, Groth B, Linsley PS, Green JM, Thompson CB, Kappler JW, Marrack P. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol 158(10):4714–20.


Walsh K, Alexander GJ. 2001. Update on chronic viral hepatitis. Postgrad Med J 77(910):498–505.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement